


# Get life-saving therapies to patients faster



## Three innovative solutions that fast-track ADC development and minimize risks

Hello [Firstname],

In recent years, antibody drug conjugates (ADCs) have revolutionized drug delivery systems. However, ADC development is costly, complex, and time-consuming.

ChetoSensar™ technology, DOLCore™ advanced intermediate and ADC Express™ services have been specifically designed for ADCs. Each is backed by decades of experience and can help get your product to market faster and with less risk.

[FAST-TRACK NOW](#)

### ChetoSensar™ technology: Overcome ADC solubility challenges

This technology already has a demonstrated track-record of successfully increasing the hydrophilicity of ADCs with numerous payloads, linkers and antibodies. It can help achieve a higher drug-to-antibody-ratio and higher efficacy. Doing so helps improve the therapeutic index, broadens the therapeutic window and increases ADC efficacy.

[LEARN MORE](#)

### DOLCore™ advanced intermediate: Synthesize dolastatin payloads in 4 steps or less

Reduce the number of synthesis steps and save time with this ground breaking technology. Dolastatin synthesis can take up to 20 steps depending on the specific linker and payload needs. This solution can be modified to produce dolastatin payloads in just four or fewer steps.

[FIND OUT MORE](#)

### ADC Express™ services: For rapid small-scale production of ADCs

ADC Express™ leverages established bio-conjugation processes and analytical platforms. Simply define the initial monoclonal antibody, linker, and payload. Easily pair different payload and solubilizing linker products including ChetoSensar™ to simplify candidate selection and get your ADC to the market faster.

[SEE HOW](#)

**Want to find out more about speeding up your ADC programs? Contact us today for more information or to request samples.**

[GET MORE INFORMATION](#)**MERCK**

The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.

Merck KGaA  
Frankfurter Strasse 250, 64293 Darmstadt, Germany  
Phone +49 6151 72 0 · Fax +49 6151 72 2000 · merckgroup.com  
Corporation with General Partners  
Commercial Register AG Darmstadt HRB 6164  
Registered Office: Darmstadt  
Chairman of the Supervisory Board: Wolfgang Büchele  
Executive Board and General Partners: Stefan Oschmann (Chairman and CEO), Belén Garijo, Kai Beckmann, Peter Guenter, Matthias Heinzel, Marcus Kuhnert

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Merck, the vibrant M, SAFC, ChetoSensar, DOLCore and ADC Express are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

Merck is committed to never sending unwelcome or unsolicited email. Based on the profile you provided, we believe that you may find this message valuable and informative. If not, [update your preferences](#), or [opt-out](#) all of future informational and promotional emails. [Privacy Policy](#).

